No Data
Royalty Pharma Plc (NASDAQ:RPRX) Is Largely Controlled by Institutional Shareholders Who Own 70% of the Company
Express News | Royalty Pharma: PTC Therapeutics Exercised Option to Sell Half of Retained Royalties on Roche's Evrysdi to Co's Unit for About $242 Mln Upfront
Declining Stock and Decent Financials: Is The Market Wrong About Royalty Pharma Plc (NASDAQ:RPRX)?
Royalty Pharma (NASDAQ:RPRX) has had a rough three months with its share price down 8.9%. However, stock prices are usually driven by a company's financials over the long term, which in this case lo
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks.
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $50
Goldman Sachs analyst Chris Shibutani maintains $Royalty Pharma(RPRX.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 44.1% a
Express News | Royalty Pharma conducted a underwriting agreement on June 3, selling $500 million senior notes with a 5.150% yield that mature in 2029 to underwriters.